Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK-rearranged lung cancer.
Dietz S, Christopoulos P, Gu L, Volckmar AL, Endris V, Yuan Z, Ogrodnik SJ, Zemojtel T, Heussel CP, Schneider MA, Meister M, Muley T, Reck M, Schlesner M, Thomas M, Stenzinger A, Sültmann H. Dietz S, et al. Cold Spring Harb Mol Case Stud. 2019 Dec 13;5(6):a004630. doi: 10.1101/mcs.a004630. Print 2019 Dec. Cold Spring Harb Mol Case Stud. 2019. PMID: 31753813 Free PMC article.
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S, Christopoulos P, Yuan Z, Angeles AK, Gu L, Volckmar AL, Ogrodnik SJ, Janke F, Fratte CD, Zemojtel T, Schneider MA, Kazdal D, Endris V, Meister M, Muley T, Cecchin E, Reck M, Schlesner M, Thomas M, Stenzinger A, Sültmann H. Dietz S, et al. EBioMedicine. 2020 Dec;62:103103. doi: 10.1016/j.ebiom.2020.103103. Epub 2020 Nov 9. EBioMedicine. 2020. PMID: 33161228 Free PMC article.
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.
Christopoulos P, Dietz S, Angeles AK, Rheinheimer S, Kazdal D, Volckmar AL, Janke F, Endris V, Meister M, Kriegsmann M, Zemojtel T, Reck M, Stenzinger A, Thomas M, Sültmann H. Christopoulos P, et al. Among authors: dietz s. Transl Lung Cancer Res. 2021 May;10(5):2118-2131. doi: 10.21037/tlcr-21-32. Transl Lung Cancer Res. 2021. PMID: 34164264 Free PMC article.
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.
Christopoulos P, Dietz S, Kirchner M, Volckmar AL, Endris V, Neumann O, Ogrodnik S, Heussel CP, Herth FJ, Eichhorn M, Meister M, Budczies J, Allgäuer M, Leichsenring J, Zemojtel T, Bischoff H, Schirmacher P, Thomas M, Sültmann H, Stenzinger A. Christopoulos P, et al. Among authors: dietz s. Cancers (Basel). 2019 Jan 21;11(1):124. doi: 10.3390/cancers11010124. Cancers (Basel). 2019. PMID: 30669647 Free PMC article.
Defining molecular risk in ALK+ NSCLC.
Christopoulos P, Budczies J, Kirchner M, Dietz S, Sültmann H, Thomas M, Stenzinger A. Christopoulos P, et al. Among authors: dietz s. Oncotarget. 2019 May 3;10(33):3093-3103. doi: 10.18632/oncotarget.26886. eCollection 2019 May 3. Oncotarget. 2019. PMID: 31139322 Free PMC article.
Circulating MicroRNAs as Potential Biomarkers for Lung Cancer.
Müller S, Janke F, Dietz S, Sültmann H. Müller S, et al. Among authors: dietz s. Recent Results Cancer Res. 2020;215:299-318. doi: 10.1007/978-3-030-26439-0_16. Recent Results Cancer Res. 2020. PMID: 31605236 Review.
Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages.
Janke F, Bozorgmehr F, Wrenger S, Dietz S, Heussel CP, Heussel G, Silva CF, Rheinheimer S, Feisst M, Thomas M, Golpon H, Günther A, Sültmann H, Muley T, Janciauskiene S, Meister M, Schneider MA. Janke F, et al. Among authors: dietz s. Cancers (Basel). 2020 Apr 12;12(4):954. doi: 10.3390/cancers12040954. Cancers (Basel). 2020. PMID: 32290637 Free PMC article.
236 results